DB2313|cas:2170606-74-1|西域试剂

DB2313,98.13%

产品编号：Bellancom-124629| CAS NO：2170606-74-1| 分子式：C₄₂H₄₁FN₈O₂| 分子量：708.83

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-124629	￥1500.00	杭州北京（现货）
Bellancom-124629	￥2500.00	杭州北京（现货）
Bellancom-124629	￥5500.00	杭州北京（现货）
Bellancom-124629	￥9500.00	杭州北京（现货）
Bellancom-124629	￥15500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DB2313

产品介绍

DB2313 是一种有效的转录因子 PU.1 抑制剂，apoptosis 为 14 nM。DB2313 破坏了 PU.1 与靶基因启动子的相互作用。DB2313 可诱导急性髓细胞性白血病 (AML) 细胞凋亡 (apoptosis)，并具有抗癌作用。

生物活性

DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects.

体外研究

DB2313 treatment leads to a profound decrease in the growth of PU.1 URE^–/– acute myeloid leukemia (AML) cells (IC₅₀ of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE^–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating.
In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE^–/– AML cells
Dosage:	17 mg/kg
Administration:	Intraperitoneal injection; three times per week; for 3 weeks
Result:	Decreased tumor burden and resulted in increased survival.

体内研究

DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE^–/– AML cells
Dosage:	17 mg/kg
Administration:	Intraperitoneal injection; three times per week; for 3 weeks
Result:	Decreased tumor burden and resulted in increased survival.

性状

Solid

溶解性数据

In Vitro:

DMSO : 3.7 mg/mL (5.22 mM; ultrasonic and warming and heat to 70°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4108 mL	7.0539 mL	14.1078 mL
5 mM	0.2822 mL	1.4108 mL	2.8216 mL
10 mM	---	---	---

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶